2-[2-(Azocan-1-yl)ethyl]guanidine;guanidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[2-(Azocan-1-yl)ethyl]guanidine;guanidine
• 英文别名: 2-[2-(azocan-1-yl)ethyl]guanidine;guanidine
• 化学式: C11H27N7
• 分子量: 257.38
• InChiKey: JUJQWALMPPJYQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.64
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  144
• 氢给体数：
  5
• 氢受体数：
  3

文献信息

• THERAPY FOR COMPLICATIONS OF DIABETES
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20140073574A1

  公开（公告）日：2014-03-13

  A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ET A ) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ET A receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ET A receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ET A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ET A receptor antagonist.